Purpose: To investigate the effect of atractylenolide on recurrent spontaneous abortion (RSA).Methods: The HTR-8/SVneo was established as an in vitro cell model of RSA. Cell viability and proliferation were determined using CCK8 and BrdU staining, while cell migration and invasion were determined by cell scratch and transwell assays.Results: Atractylenolide significantly increased cell viability, and enhanced the number of BrdU-positive cells of HTR-8/SVneo (p < 0.01). Atractylenolide also significantly promoted cell migration and invasion (p < 0.01), and increased protein expression of MMP-9, MMP-2, and N-cadherin, but reduced Ecadherin. Atractylenolide also increased the phosphorylation of ERK (p < 0.01).Conclusion: Atractylenolide enhances cell proliferation and migration of HTR-8/SVneo through activation of ERK signaling. Further studies using animal models are recommended to determine the protective role of atractylenolide against RSA, in vivo.
{"title":"Atractylenolide promotes trophoblast cell proliferation and migration in recurrent spontaneous abortion via ERK pathway","authors":"Beili Lv, Haiyan Wang, Xinrong Li","doi":"10.4314/tjpr.v22i8.3","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.3","url":null,"abstract":"Purpose: To investigate the effect of atractylenolide on recurrent spontaneous abortion (RSA).Methods: The HTR-8/SVneo was established as an in vitro cell model of RSA. Cell viability and proliferation were determined using CCK8 and BrdU staining, while cell migration and invasion were determined by cell scratch and transwell assays.Results: Atractylenolide significantly increased cell viability, and enhanced the number of BrdU-positive cells of HTR-8/SVneo (p < 0.01). Atractylenolide also significantly promoted cell migration and invasion (p < 0.01), and increased protein expression of MMP-9, MMP-2, and N-cadherin, but reduced Ecadherin. Atractylenolide also increased the phosphorylation of ERK (p < 0.01).Conclusion: Atractylenolide enhances cell proliferation and migration of HTR-8/SVneo through activation of ERK signaling. Further studies using animal models are recommended to determine the protective role of atractylenolide against RSA, in vivo.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To evaluate the effect and underlying mechanisms of action of cardamine on the progression of bladder cancer (BC).Methods: Human bladder epithelium immortalized cell line (SV-HUC-1) and human bladder cancer (BC) cell lines (T24 and UM-UC-3) were used in this investigation. They were treated with cardamine at concentrations of 0, 15, 30, 60 or 120 μmol/L. Cell viability was determined using cell counting kit 8(CCK-8) assay while 5-ethynyl-2'-deoxyuridine (Edu) assay was used to assess cell proliferation. Cell apoptosis as well as reactive oxygen species (ROS) accumulation were determined by flow cytometry whereas glucose uptake, adenosine triphosphate (ATP) level and lactate production were determined using their respective assay kits. Furthermore, the expression levels of nuclear factor level (erythroidderived 2)-like 2 (Nrf2), NAD(P)H, quinone oxidoreductase 1 (NQO1), protein kinase B (AKT), phosphorylated-AKT (p-AKT), phosphatidylinositol 3-kinase (PI3K), p-PI3K, mechanistic target of rapamycin kinase (mTOR) and p-mTOR were evaluated by western blot analysis.Results: Cardamine significantly reduced cell viability and inhibited cell proliferation in BC cells in a dose-dependent manner, but did not affect human normal cells. In addition, treatment with the compound induced apoptosis in BC cells; the higher the concentration, the higher the apoptosis level. Besides, cardamine administration suppressed aerobic glycolysis, and decreased the nuclear factor level (Nrf2) level, thereby increasing ROS production in a concentration-dependent manner.Furthermore, it blocked the activation of PI3K/AKT/mTOR signal cascade.Conclusion: Cardamine inhibits glycolysis and PI3K/AKT/mTOR pathway, and also promotes apoptosis as well as oxidative stress in BC cells. Thus, the compound is a potential therapeutic reagent for BC.
{"title":"Cardamonin suppresses glycolysis and induces oxidative stress by inhibiting PI3K/AKT/mTOR pathway in bladder cancer cells","authors":"Ping Li, Chaopeng Tang, Dian Fu, Xiaofeng Xu, Jingping Ge, Ruipeng Jia","doi":"10.4314/tjpr.v22i8.2","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.2","url":null,"abstract":"Purpose: To evaluate the effect and underlying mechanisms of action of cardamine on the progression of bladder cancer (BC).Methods: Human bladder epithelium immortalized cell line (SV-HUC-1) and human bladder cancer (BC) cell lines (T24 and UM-UC-3) were used in this investigation. They were treated with cardamine at concentrations of 0, 15, 30, 60 or 120 μmol/L. Cell viability was determined using cell counting kit 8(CCK-8) assay while 5-ethynyl-2'-deoxyuridine (Edu) assay was used to assess cell proliferation. Cell apoptosis as well as reactive oxygen species (ROS) accumulation were determined by flow cytometry whereas glucose uptake, adenosine triphosphate (ATP) level and lactate production were determined using their respective assay kits. Furthermore, the expression levels of nuclear factor level (erythroidderived 2)-like 2 (Nrf2), NAD(P)H, quinone oxidoreductase 1 (NQO1), protein kinase B (AKT), phosphorylated-AKT (p-AKT), phosphatidylinositol 3-kinase (PI3K), p-PI3K, mechanistic target of rapamycin kinase (mTOR) and p-mTOR were evaluated by western blot analysis.Results: Cardamine significantly reduced cell viability and inhibited cell proliferation in BC cells in a dose-dependent manner, but did not affect human normal cells. In addition, treatment with the compound induced apoptosis in BC cells; the higher the concentration, the higher the apoptosis level. Besides, cardamine administration suppressed aerobic glycolysis, and decreased the nuclear factor level (Nrf2) level, thereby increasing ROS production in a concentration-dependent manner.Furthermore, it blocked the activation of PI3K/AKT/mTOR signal cascade.Conclusion: Cardamine inhibits glycolysis and PI3K/AKT/mTOR pathway, and also promotes apoptosis as well as oxidative stress in BC cells. Thus, the compound is a potential therapeutic reagent for BC.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To compare clinical efficacy of pure silica gel and chitosan quaternary ammonium salt silica gel (SQASC) in treatment of hypertrophic scars.Methods: Eighty-four patients with hypertrophic scars, who were admitted to hospital, were randomly divided into study group and control group with 42 patients in each group. Study group was treated with SQASC while control group was treated with pure silica gel. Scar scores (Vancouver scar score, VSS), scar aesthetics (Patient and observer scar assessment scale, POSAS), symptom improvement and adverse reactions were compared between groups before and after treatment.Results: Before treatment, there were no differences in VSS and POSAS scores for each aspect between groups. After treatment, VSS and POSAS scores for each aspect in study group were significantly lower than those in control group (p < 0.05). Congestion, itching, pain disappearance and thickness reduction occurred significantly earlier in study group than in control group (p < 0.05). Incidence of adverse reactions in study group was 4.76 %, which was significantly lower than 19.05% in control group (p < 0.05).Conclusion: Compared with pure silica gel, SQASC effectively alleviates symptoms of hypertrophic scars and aesthetics with fewer adverse effects. In future studies, sample size will be increased and study duration will be extended appropriately.
{"title":"A comparative study of the efficacy and safety of pure silica gel and chitosan quaternary ammonium salt silica gel in hypertrophic scar treatment","authors":"Shenglin Wu, Yuan Jiang","doi":"10.4314/tjpr.v22i8.25","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.25","url":null,"abstract":"Purpose: To compare clinical efficacy of pure silica gel and chitosan quaternary ammonium salt silica gel (SQASC) in treatment of hypertrophic scars.Methods: Eighty-four patients with hypertrophic scars, who were admitted to hospital, were randomly divided into study group and control group with 42 patients in each group. Study group was treated with SQASC while control group was treated with pure silica gel. Scar scores (Vancouver scar score, VSS), scar aesthetics (Patient and observer scar assessment scale, POSAS), symptom improvement and adverse reactions were compared between groups before and after treatment.Results: Before treatment, there were no differences in VSS and POSAS scores for each aspect between groups. After treatment, VSS and POSAS scores for each aspect in study group were significantly lower than those in control group (p < 0.05). Congestion, itching, pain disappearance and thickness reduction occurred significantly earlier in study group than in control group (p < 0.05). Incidence of adverse reactions in study group was 4.76 %, which was significantly lower than 19.05% in control group (p < 0.05).Conclusion: Compared with pure silica gel, SQASC effectively alleviates symptoms of hypertrophic scars and aesthetics with fewer adverse effects. In future studies, sample size will be increased and study duration will be extended appropriately.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yanrong Song, Yu Guo, Jie Qin, Xiaojing Jia, Chentao Yang
Purpose: To investigate the effect of micro-ribonucleic acid (miR)-208a on heart failure (HF) in rats through β-catenin pathway.Methods: A total of 24 specific pathogen-free female Sprague-Dawley rats were enrolled and randomly divided into 3 equal groups, namely, control (normal group), model, and study group (miR-208a), with 8 rats each. Echocardiography was utilized to evaluate cardiac function, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was applied to examine cardiomyocyte apoptosis. Finally, expression levels of interleukin (IL)-6 and IL-10 were determined using enzymelinked immunosorbent assay (ELISA). Expression of matrix metalloproteinases (MMPs) was determined via immunohistochemistry assay, while western blotting was used to measure expression of β-catenin.Results: The mRNA expression level of miR-208a was significantly lower in model group than control and study group (p < 0.05). Cardiac function of rats in model group was significantly better than other groups (p < 0.05). Cardiomyocyte apoptosis was significantly increased in model group than in other groups (p < 0.05). Furthermore, expression levels of MMPs, IL-6 and IL-10 in model group were elevated in comparison with those in study and control groups (p < 0.05).Conclusion: MiR-208a reduces inflammatory response and deposition of extracellular matrix in rats with HF through inhibition of β-catenin signaling pathway, thereby restoring cardiac function.
{"title":"MiR-208a reduces inflammatory responses in heart failure rats through β-catenin pathway","authors":"Yanrong Song, Yu Guo, Jie Qin, Xiaojing Jia, Chentao Yang","doi":"10.4314/tjpr.v22i8.6","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.6","url":null,"abstract":"Purpose: To investigate the effect of micro-ribonucleic acid (miR)-208a on heart failure (HF) in rats through β-catenin pathway.Methods: A total of 24 specific pathogen-free female Sprague-Dawley rats were enrolled and randomly divided into 3 equal groups, namely, control (normal group), model, and study group (miR-208a), with 8 rats each. Echocardiography was utilized to evaluate cardiac function, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was applied to examine cardiomyocyte apoptosis. Finally, expression levels of interleukin (IL)-6 and IL-10 were determined using enzymelinked immunosorbent assay (ELISA). Expression of matrix metalloproteinases (MMPs) was determined via immunohistochemistry assay, while western blotting was used to measure expression of β-catenin.Results: The mRNA expression level of miR-208a was significantly lower in model group than control and study group (p < 0.05). Cardiac function of rats in model group was significantly better than other groups (p < 0.05). Cardiomyocyte apoptosis was significantly increased in model group than in other groups (p < 0.05). Furthermore, expression levels of MMPs, IL-6 and IL-10 in model group were elevated in comparison with those in study and control groups (p < 0.05).Conclusion: MiR-208a reduces inflammatory response and deposition of extracellular matrix in rats with HF through inhibition of β-catenin signaling pathway, thereby restoring cardiac function.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the effect of sevoflurane on renal ischemia-reperfusion injury (IRI) in rats and its regulatory effect on reperfusion injury salvage kinase (RISK) signaling pathway.Methods: A total of thirty (30) Sprague-Dawley rats were randomly divided into sham, model and sevoflurane groups with 10 animals per group. Renal IRI models were created in model and sevoflurane groups, while sham group had no ligation. Renal injury was determined using hematoxylin and eosin (HE) staining. Blood urea nitrogen (BUN) and serum creatinine (Scr) levels were assayed while apoptosis was determined via terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. Enzyme-linked immunosorbent assay (ELISA) was used to assess malonaldehyde (MDA) content and inflammatory factors in kidney tissues and peripheral blood, respectively. Reactive oxygen species (ROS) level was determined using 2,7-dichlorodi-hydro fluorescein diacetate (DCFHDA) while Western blotting was used to determine the expression of apoptosis- and RISK signaling pathway-related proteins in kidney tissues.Results: Compared to model group, renal injury in sevoflurane group rats was significantly alleviated (p < 0.01). The levels of BUN and Scr in peripheral blood, apoptosis level in kidney tissues, MDA content and ROS level in kidney tissues, interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and IL-6 content, and content of caspase-3 protein in kidney tissues were significantly reduced (p < 0.01), whereas IL-10 content, Bcl-2/Bax ratio and expression levels of p-ERK1/2, p-Akt and phosphorylated glycogen synthase kinase 3β (p-GSK-3β) were significantly increased (p < 0.01) in the sevoflurane group.Conclusion: Sevoflurane represses the release of inflammatory factors, lowers ROS level and apoptosis of renal cells and improves renal function through activation of RISK signaling pathway in kidney tissues of rats with renal IRI. Thus, sevoflurane is a potential agent for the treatment of IRI.
{"title":"Sevoflurane improves renal ischemia-reperfusion injury in rats through RISK signaling pathway","authors":"Bo Wang, Xin Yan, Xin Zou","doi":"10.4314/tjpr.v22i8.10","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.10","url":null,"abstract":"Purpose: To investigate the effect of sevoflurane on renal ischemia-reperfusion injury (IRI) in rats and its regulatory effect on reperfusion injury salvage kinase (RISK) signaling pathway.Methods: A total of thirty (30) Sprague-Dawley rats were randomly divided into sham, model and sevoflurane groups with 10 animals per group. Renal IRI models were created in model and sevoflurane groups, while sham group had no ligation. Renal injury was determined using hematoxylin and eosin (HE) staining. Blood urea nitrogen (BUN) and serum creatinine (Scr) levels were assayed while apoptosis was determined via terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. Enzyme-linked immunosorbent assay (ELISA) was used to assess malonaldehyde (MDA) content and inflammatory factors in kidney tissues and peripheral blood, respectively. Reactive oxygen species (ROS) level was determined using 2,7-dichlorodi-hydro fluorescein diacetate (DCFHDA) while Western blotting was used to determine the expression of apoptosis- and RISK signaling pathway-related proteins in kidney tissues.Results: Compared to model group, renal injury in sevoflurane group rats was significantly alleviated (p < 0.01). The levels of BUN and Scr in peripheral blood, apoptosis level in kidney tissues, MDA content and ROS level in kidney tissues, interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and IL-6 content, and content of caspase-3 protein in kidney tissues were significantly reduced (p < 0.01), whereas IL-10 content, Bcl-2/Bax ratio and expression levels of p-ERK1/2, p-Akt and phosphorylated glycogen synthase kinase 3β (p-GSK-3β) were significantly increased (p < 0.01) in the sevoflurane group.Conclusion: Sevoflurane represses the release of inflammatory factors, lowers ROS level and apoptosis of renal cells and improves renal function through activation of RISK signaling pathway in kidney tissues of rats with renal IRI. Thus, sevoflurane is a potential agent for the treatment of IRI.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yanxi Li, Jun Peng, Yong Huang, Yicun Man, Xin Wen, Xi Yang
Purpose: To investigate the regulatory influence of Prok1 on apoptotic and proliferative changes in PCOS, and the implication of Pi3k/Akt/nf-κ B signaling pathway in the process.Methods: Ovarian granulosa cells from a rat model of PCOS were assigned to control and si-Prok1 groups, after cell culture. Then, control lentivirus and Prok1 siRNA lentivirus (50 μL each) were added to the cells to the groups, respectively. Cell cycle ratio and apoptosis in the two groups were determined using flow cytometry, while Pi3k/Akt signal route-linked protein levels were assayed by immunoblot method.Results: The proportions of cells at G0/G1 and S phases of the cell cycle in si-Prok1 group were significantly lower than those in the control group, but G2/M phase cell population was significantly higher, relative to the control (p < 0.01). There was significant down-regulation of protein expressions of cyclin A2 and cycline1 in si-Prok1 group, relative to control group, but p21 protein level was significantly higher in si-Prok1 group (p < 0.05). There was a significantly higher apoptosis in si-Prok1 group. In the si-Prok1 cells, there were significant increases in protein levels of Bcl-2, cleaved caspase-9 and caspase-3, relative to control group, while protein expression levels of Bax, p-Pi3k and p-Akt in si-Prok1 group were significantly lower than the corresponding control values (p < 0.05).Conclusion: si-Prok1 arrests cell cycle, induces apoptotic changes, and inhibits the proliferation of ovarian granulosa cells through a mechanism related to the regulation of Pi3k/Akt signaling pathway. Therefore, it might play a potential role in the treatment of polycystic ovary syndrome.
{"title":"Prok1 regulates the proliferation and apoptosis of ovarian granulosa cells in polycystic ovary syndrome via Pi3k/Akt/nf-κ B signaling route","authors":"Yanxi Li, Jun Peng, Yong Huang, Yicun Man, Xin Wen, Xi Yang","doi":"10.4314/tjpr.v22i8.1","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.1","url":null,"abstract":"Purpose: To investigate the regulatory influence of Prok1 on apoptotic and proliferative changes in PCOS, and the implication of Pi3k/Akt/nf-κ B signaling pathway in the process.Methods: Ovarian granulosa cells from a rat model of PCOS were assigned to control and si-Prok1 groups, after cell culture. Then, control lentivirus and Prok1 siRNA lentivirus (50 μL each) were added to the cells to the groups, respectively. Cell cycle ratio and apoptosis in the two groups were determined using flow cytometry, while Pi3k/Akt signal route-linked protein levels were assayed by immunoblot method.Results: The proportions of cells at G0/G1 and S phases of the cell cycle in si-Prok1 group were significantly lower than those in the control group, but G2/M phase cell population was significantly higher, relative to the control (p < 0.01). There was significant down-regulation of protein expressions of cyclin A2 and cycline1 in si-Prok1 group, relative to control group, but p21 protein level was significantly higher in si-Prok1 group (p < 0.05). There was a significantly higher apoptosis in si-Prok1 group. In the si-Prok1 cells, there were significant increases in protein levels of Bcl-2, cleaved caspase-9 and caspase-3, relative to control group, while protein expression levels of Bax, p-Pi3k and p-Akt in si-Prok1 group were significantly lower than the corresponding control values (p < 0.05).Conclusion: si-Prok1 arrests cell cycle, induces apoptotic changes, and inhibits the proliferation of ovarian granulosa cells through a mechanism related to the regulation of Pi3k/Akt signaling pathway. Therefore, it might play a potential role in the treatment of polycystic ovary syndrome.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To elucidate the basis for the cardioprotective effect of dexmedetomidine pre-treatment on ROS-induced myocardial ischemia-reperfusion injury (IRI) in rats.Methods: Sixty Sprague-Dawley (SD) rats were assigned to sham, model and dexmedetomidine intervention groups, each having 20 rats. Myocardial IRI was induced in the model and dexmedetomidine intervention groups using modified suture method. In sham group, chests of rats were opened, but without ligation, while dexmedetomidine intervention group was pre-treated with dexmedetomidine (5 μg/kg) before establishment of the IRI model. Protein expressions of adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK) was determined by Western blot assay. Mean fluorescence intensity of ROS was measured using flow cytometry.Results: AMPK protein was significantly down-regulated in model rats, relative to sham rats, but significantly higher in dexmedetomidine intervention rats (p < 0.05). In model rats, mean ROS fluorescence intensity and degree of apoptosis of cardiomyocytes were higher than the corresponding values in sham rats (p < 0.05), but lower in dexmedetomidine intervention group.Conclusion: Dexmedetomidine reduces oxidative stress in myocardial tissue and exerts a protective role by activating AMPK pathway and inhibiting mitochondrial generation of ROS. Therefore, this compound might have a potential clinical role in the management of IRI.
{"title":"Dexmedetomidine pre-conditioning induces inhibition of ROS in myocardial ischemia-reperfusion injury in rats through AMPK pathway","authors":"Shanhu Wu, Wanping Hong, Xue'e Su, Jinwei Liang","doi":"10.4314/tjpr.v22i8.11","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.11","url":null,"abstract":"Purpose: To elucidate the basis for the cardioprotective effect of dexmedetomidine pre-treatment on ROS-induced myocardial ischemia-reperfusion injury (IRI) in rats.Methods: Sixty Sprague-Dawley (SD) rats were assigned to sham, model and dexmedetomidine intervention groups, each having 20 rats. Myocardial IRI was induced in the model and dexmedetomidine intervention groups using modified suture method. In sham group, chests of rats were opened, but without ligation, while dexmedetomidine intervention group was pre-treated with dexmedetomidine (5 μg/kg) before establishment of the IRI model. Protein expressions of adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK) was determined by Western blot assay. Mean fluorescence intensity of ROS was measured using flow cytometry.Results: AMPK protein was significantly down-regulated in model rats, relative to sham rats, but significantly higher in dexmedetomidine intervention rats (p < 0.05). In model rats, mean ROS fluorescence intensity and degree of apoptosis of cardiomyocytes were higher than the corresponding values in sham rats (p < 0.05), but lower in dexmedetomidine intervention group.Conclusion: Dexmedetomidine reduces oxidative stress in myocardial tissue and exerts a protective role by activating AMPK pathway and inhibiting mitochondrial generation of ROS. Therefore, this compound might have a potential clinical role in the management of IRI.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"2013 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hoang Nhan Ho, Van Anh Tuan Nguyen, Nguyen Anh Thu Ho, Hoang Hao Le
This article previously published in Volume 22 Issue 6 of this journal in June 2023 has been retracted in line with the guidelines from the Committee on Publication Ethics (COPE, http://publicationethics.org /resources /guidelines). This was a follow up to the report by somebody identified as VU Nguyen (email: nguyenvu81@protonmail.com) of the duplicate publication of an article earlier published in 2020 (available at http://125.212.201.8:6008 / ViewOnline?bitstid=0d585588-2d02-4839-907a-92998674bb4d & type=1) in Vietnamese where a figure and some text in the article were repeated in the article published in this journal.
This action was taken after thorough investigation of the plagiarism report and follow-up comments from both the corresponding author and Nguyen VU against the guidelines of the Committee on Publication Ethics (COPE).
Retraction: Ho HN, Nguyen VA, Ho NA, Le HH. Development of a hydrogel containing metronidazole-loaded Eudragit RS 100 nanoparticles for buccal drug delivery. Trop J Pharm Res 2023; 22(6):1147- 1154 doi: 10.4314/tjpr.v22i6.1.
{"title":"Retracted: Development of a hydrogel containing metronidazole-loaded Eudragit RS 100 nanoparticles for buccal drug delivery","authors":"Hoang Nhan Ho, Van Anh Tuan Nguyen, Nguyen Anh Thu Ho, Hoang Hao Le","doi":"10.4314/tjpr.v22i8.30","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.30","url":null,"abstract":"This article previously published in Volume 22 Issue 6 of this journal in June 2023 has been retracted in line with the guidelines from the Committee on Publication Ethics (COPE, http://publicationethics.org /resources /guidelines). This was a follow up to the report by somebody identified as VU Nguyen (email: nguyenvu81@protonmail.com) of the duplicate publication of an article earlier published in 2020 (available at http://125.212.201.8:6008 / ViewOnline?bitstid=0d585588-2d02-4839-907a-92998674bb4d & type=1) in Vietnamese where a figure and some text in the article were repeated in the article published in this journal.
 This action was taken after thorough investigation of the plagiarism report and follow-up comments from both the corresponding author and Nguyen VU against the guidelines of the Committee on Publication Ethics (COPE).
 Retraction: Ho HN, Nguyen VA, Ho NA, Le HH. Development of a hydrogel containing metronidazole-loaded Eudragit RS 100 nanoparticles for buccal drug delivery. Trop J Pharm Res 2023; 22(6):1147- 1154 doi: 10.4314/tjpr.v22i6.1.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the clinical impact of combined application of acetylcysteine and methylprednisolone in treating paraquat poisoning (PQP).Methods: The clinical data of 92 PQP patients who received treatment in our hospital for 1 year were analyzed. The patients were equally divided into control group (CG) and study group (SG), based on treatment plans. All patients underwent routine acute-phase treatment, while SG was additionally treated with acetylcysteine in combination with methylprednisolone. After treatment, the renal function, pulmonary fibrosis indices and inflammatory factor levels of both groups were determined.Results: During the 1 - 4 weeks of treatment, there was no statistical difference in the survival rates of patients at various time periods (p > 0.05). After treatment, there were markedly lower levels of blood urea nitrogen (BUN) and serum creatinine (SCr) in SG than in CG. There was lower incidence of pulmonary fibrosis in SG than in CG, although the difference was not significant. Patients in SG had lower HRCT scores and levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) than those in CG (p < 0.05).Conclusion: Acetylcysteine in combination with methylprednisolone significantly reduces the degree of pulmonary fibrosis and improves renal function and inflammatory levels. It has a positive implication for early treatment of patients, especially for the prognosis of patients with mild-to-moderate poisoning. Therefore, the combined therapy has potential for clinical application.
{"title":"Efficacy of combined use of acetylcysteine and methylprednisolone in the treatment of paraquat poisoning","authors":"Yudan Yang, Pingping Zhou, Qingmian Xiao, Yongyan Han, Weizhan Wang, Yulan Yu","doi":"10.4314/tjpr.v22i8.26","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.26","url":null,"abstract":"Purpose: To investigate the clinical impact of combined application of acetylcysteine and methylprednisolone in treating paraquat poisoning (PQP).Methods: The clinical data of 92 PQP patients who received treatment in our hospital for 1 year were analyzed. The patients were equally divided into control group (CG) and study group (SG), based on treatment plans. All patients underwent routine acute-phase treatment, while SG was additionally treated with acetylcysteine in combination with methylprednisolone. After treatment, the renal function, pulmonary fibrosis indices and inflammatory factor levels of both groups were determined.Results: During the 1 - 4 weeks of treatment, there was no statistical difference in the survival rates of patients at various time periods (p > 0.05). After treatment, there were markedly lower levels of blood urea nitrogen (BUN) and serum creatinine (SCr) in SG than in CG. There was lower incidence of pulmonary fibrosis in SG than in CG, although the difference was not significant. Patients in SG had lower HRCT scores and levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) than those in CG (p < 0.05).Conclusion: Acetylcysteine in combination with methylprednisolone significantly reduces the degree of pulmonary fibrosis and improves renal function and inflammatory levels. It has a positive implication for early treatment of patients, especially for the prognosis of patients with mild-to-moderate poisoning. Therefore, the combined therapy has potential for clinical application.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To assess the efficacy of dexmedetomidine in the prevention and treatment of postanesthetic shivering in cesarean section.Methods: A total of 144 pregnant women who underwent anesthesia for cesarean section between March and December 2022 were randomly divided into the study group (n = 72) and control group (n = 72). The pregnant women were given combined spinal-epidural anesthesia. Following childbirth, those in the study group were given dexmedetomidine, while those in the control group were given normalsaline. The dose of spinal anesthesia was administered based on the following criteria: intraoperative infusion, atropine usage, ephedrine usage, intraoperative bleeding, intraoperative dosage, mean arterial pressure, heart rate, blood oxygen saturation, incidence of shivering, and sedation score. Incidence of adverse reactions were recorded and compared between the two groups.Results: Intraoperative infusion volume, bleeding volume, levels of atropine and ephedrine usage, and spinal anesthesia dose were similar between the two groups (p > 0.05). At 10 min post-treatment, the study group had lower mean arterial pressure, heart rate and incidence of postanesthetic shivering, as well as higher postoperative sedation score than the control group. Compared with the control group, the study group had slightly higher incidence of pregnancy-related adverse reactions, but the difference was non-significant.Conclusion: Dexmedetomidine has good efficacy in preventing and treating postanesthetic shivering in cesarean section patients. However, further clinical trials are required prior to its adoption in clinical practice.
{"title":"Efficacy of dexmedetomidine in the prevention and treatment of postanesthetic shivering after cesarean section","authors":"Yi Wang, Xianjie Zhang","doi":"10.4314/tjpr.v22i8.23","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.23","url":null,"abstract":"Purpose: To assess the efficacy of dexmedetomidine in the prevention and treatment of postanesthetic shivering in cesarean section.Methods: A total of 144 pregnant women who underwent anesthesia for cesarean section between March and December 2022 were randomly divided into the study group (n = 72) and control group (n = 72). The pregnant women were given combined spinal-epidural anesthesia. Following childbirth, those in the study group were given dexmedetomidine, while those in the control group were given normalsaline. The dose of spinal anesthesia was administered based on the following criteria: intraoperative infusion, atropine usage, ephedrine usage, intraoperative bleeding, intraoperative dosage, mean arterial pressure, heart rate, blood oxygen saturation, incidence of shivering, and sedation score. Incidence of adverse reactions were recorded and compared between the two groups.Results: Intraoperative infusion volume, bleeding volume, levels of atropine and ephedrine usage, and spinal anesthesia dose were similar between the two groups (p > 0.05). At 10 min post-treatment, the study group had lower mean arterial pressure, heart rate and incidence of postanesthetic shivering, as well as higher postoperative sedation score than the control group. Compared with the control group, the study group had slightly higher incidence of pregnancy-related adverse reactions, but the difference was non-significant.Conclusion: Dexmedetomidine has good efficacy in preventing and treating postanesthetic shivering in cesarean section patients. However, further clinical trials are required prior to its adoption in clinical practice.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：